Humana (NYSE:HUM) Given New $230.00 Price Target at Raymond James Financial

Humana (NYSE:HUM) had its price target lowered by Raymond James Financial from $340.00 to $230.00 in a report published on Friday,MarketScreener reports. The firm currently has an outperform rating on the insurance provider’s stock.

Several other research analysts have also issued reports on HUM. Cantor Fitzgerald lowered their price target on shares of Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a report on Thursday. Robert W. Baird dropped their target price on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Royal Bank Of Canada downgraded Humana from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $322.00 to $189.00 in a report on Thursday. Truist Financial lowered their price objective on Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Finally, TD Cowen cut their target price on Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $238.29.

Humana Stock Performance

Humana stock opened at $183.92 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02. Humana has a 1 year low of $169.61 and a 1 year high of $315.35. The company has a market capitalization of $22.12 billion, a P/E ratio of 18.73, a P/E/G ratio of 1.99 and a beta of 0.44. The business has a 50 day moving average of $244.65 and a 200-day moving average of $260.85.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. During the same quarter in the previous year, the company posted ($2.16) EPS. The business’s revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts predict that Humana will post 16.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Capital International Investors raised its position in shares of Humana by 113.9% in the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock worth $1,490,239,000 after buying an additional 3,097,571 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock valued at $907,541,000 after acquiring an additional 2,553,509 shares during the period. Norges Bank bought a new position in Humana during the 4th quarter worth approximately $456,632,000. Franklin Resources Inc. increased its stake in Humana by 914.5% in the 4th quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider’s stock worth $321,613,000 after purchasing an additional 1,131,893 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Humana by 161.5% in the third quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock valued at $446,911,000 after purchasing an additional 1,060,767 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.